Tags: Drug.
Eculizumab (INN and USAN; trade name Soliris) is a humanized monoclonal antibody that is a first-in-class terminal complement inhibitor and the first therapy approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) a rare progressive and sometimes life-threatening disease characterized by excessive destruction of red blood cells (hemolysis) and excessive blood clotting.